» Articles » PMID: 36944713

ClpC2 Protects Mycobacteria Against a Natural Antibiotic Targeting ClpC1-dependent Protein Degradation

Overview
Journal Commun Biol
Specialty Biology
Date 2023 Mar 22
PMID 36944713
Authors
Affiliations
Soon will be listed here.
Abstract

Mycobacterium tuberculosis Clp proteases are targeted by several antitubercular compounds, including cyclomarin A (CymA). CymA exerts its toxicity by binding to AAA + chaperone ClpC1. Here, we show that CymA can also bind a partial homologue of ClpC1, known as ClpC2, and we reveal the molecular basis of these interactions by determining the structure of the M. tuberculosis ClpC2:CymA complex. Furthermore, we show deletion of clpC2 in Mycobacterium smegmatis increases sensitivity to CymA. We find CymA exposure leads to a considerable upregulation of ClpC2 via a mechanism in which binding of CymA to ClpC2 prevents binding of ClpC2 to its own promoter, resulting in upregulation of its own transcription in response to CymA. Our study reveals that ClpC2 not only senses CymA, but that through this interaction it can act as a molecular sponge to counteract the toxic effects of CymA and possibly other toxins targeting essential protease component ClpC1 in mycobacteria.

Citing Articles

ApoE Mimetic Peptide COG1410 Kills via Directly Interfering ClpC's ATPase Activity.

Wang C, Ren Y, Han L, Yi P, Wang W, Zhang C Antibiotics (Basel). 2024; 13(3).

PMID: 38534713 PMC: 10967448. DOI: 10.3390/antibiotics13030278.


BacPROTACs targeting Clp protease: a promising strategy for anti-mycobacterial drug discovery.

Bonjorno A, Pavan A, Fernandes G, Scarim C, Castagnolo D, Dos Santos J Front Chem. 2024; 12:1358539.

PMID: 38357296 PMC: 10864484. DOI: 10.3389/fchem.2024.1358539.


Protein quality control: from molecular mechanisms to therapeutic intervention-EMBO workshop, May 21-26 2023, Srebreno, Croatia.

Munch C, Kirstein J Cell Stress Chaperones. 2023; 28(6):631-640.

PMID: 37731161 PMC: 10746685. DOI: 10.1007/s12192-023-01383-4.

References
1.
. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 5):760-3. DOI: 10.1107/S0907444994003112. View

2.
Choules M, Wolf N, Lee H, Anderson J, Grzelak E, Wang Y . Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus. Antimicrob Agents Chemother. 2019; 63(3). PMC: 6395927. DOI: 10.1128/AAC.02204-18. View

3.
Terwilliger T, Grosse-Kunstleve R, Afonine P, Moriarty N, Zwart P, Hung L . Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr D Biol Crystallogr. 2007; 64(Pt 1):61-9. PMC: 2394820. DOI: 10.1107/S090744490705024X. View

4.
Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P . Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021; 113 Suppl 1:S7-S12. PMC: 8433257. DOI: 10.1016/j.ijid.2021.02.107. View

5.
Kirstein J, Schlothauer T, Dougan D, Lilie H, Tischendorf G, Mogk A . Adaptor protein controlled oligomerization activates the AAA+ protein ClpC. EMBO J. 2006; 25(7):1481-91. PMC: 1440321. DOI: 10.1038/sj.emboj.7601042. View